Douglas L. Maslin
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Budget impact analysis of delgocitinib for moderate to severe Chronic Hand Eczema in the United States.
Journal: Journal of medical economics
Published: May 27, 2026
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial.
Journal: Dermatology and therapy
Published: January 07, 2026
Moderate to severe Chronic Hand Eczema in clinical practice: etiological subtypes, clinical signs and symptoms, and comorbidities-results from the RWEAL study.
Journal: The Journal of dermatological treatment
Published: January 06, 2026
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema.
Journal: Dermatology and therapy
Published: September 24, 2025
Letter: "Dupilumab for Chronic Hand Eczema: A Systematic Review and Meta-Analysis" by Riva et al. (2024).
Journal: Dermatitis : contact, atopic, occupational, drug
Published: September 12, 2025
Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart Review.
Journal: Dermatology and therapy
Published: July 15, 2025
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.
Journal: American journal of clinical dermatology
Published: February 09, 2025
A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis.
Journal: Frontiers in medicine
Published: September 11, 2023
Trichophyton rubrum-induced Majocchi's granuloma in an immunocompromised patient.
Journal: The Lancet. Infectious diseases
Published: November 15, 2022
Clinical translation of anti-inflammatory effects of Prevotella histicola in Th1, Th2, and Th17 inflammation.
Journal: Frontiers in medicine
Published: October 17, 2022
Last Updated: 09/26/2026